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A B S T R A C T
Objectives: To evaluate the impact of high-dose (HD) carbapenem-based combination therapy on clin-
ical outcome in patients with monomicrobial carbapenem-resistant Klebsiella pneumoniae (CR-KP)
bloodstream-infection (BSI).
Methods: Post hoc analysis of all adult patients with CR-KP BSI who were treated with a combination
antibiotic regimen, collected over a six-year period in six large Italian teaching hospitals. To control for
confounding effects of HD carbapenem combination on 14-day mortality, a multivariate Cox regression
analysis was performed. Due to imbalances between patients, a propensity score for receiving HD
carbapenem was added to the model.
Results: 595 patients with CR-KP BSI were analysed, 77% of isolates showed a carbapenemMIC ≥16 mg/
L, 428 (71.9%) received HD carbapenem-based combination therapy. Overall, 127 patients (21.3%) died
within 14 days after BSI onset. Multivariate analysis showed the Charlson comorbidity index (HR 1.31,
95%CI 1.20–1.43, P < 0.001), septic shock at BSI onset (HR 3.14, 95%CI 2.19–4.50, P < 0.001), and colistin-
resistant strain (HR 1.52, 95%CI 1.02–2.24, P = 0.03) were independently associated with 14-day mortality,
whereas admission to surgical ward (HR 0.44, 95%CI 0.25–0.78, P = 0.005) and HD carbapenem use (HR
0.69, 95%CI 0.47–1.00, P = 0.05) were protective factors. When adjusted for the propensity score, HD
carbapenem use showed a greater protective effect (HR 0.64, 95%CI 0.43–0.95, P = 0.03). Stratifying the
model for carbapenemMIC, the beneﬁt of HD carbapenemwas also observed for strains with carbapenem
MIC ≥16 mg/L.
Conclusions: In patients receiving combination therapy for CR-KP BSI, the use of HD carbapenem seems
to be associated with better outcome, even in the presence of high-level carbapenem resistance.
© 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
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1. Introduction
Over the last decade, the prevalence of carbapenem-resistant
Klebsiella pneumoniae (CR-KP) infections has increased world-
wide, with associated high morbidity and mortality, particularly
among patients with bloodstream infection (BSI) [1].
Given the limited number of effective and safe agents, several
strategies have been proposed to treat CR-KP infections. One of the
most supported strategies is a combination antibiotic regimen to
improve bactericidal activity, suppress the emergence of resis-
tance, and overcome the pharmacokinetic weaknesses of individual
agents. Indeed, several studies have reported lower mortality rates
(0–40%) among patients who received combination therapy com-
pared with patients who received monotherapy (40–80%) [2–7].
Recently, the positive impact of combination therapy has been shown
to be signiﬁcant, primarily in patients at high risk of dying [8].
Unfortunately, the question of which combination is superior
remains unresolved [9]. Among the different combinations, those
that included a carbapenem were associated with better outcome
in some studies [4–7]. In an Italian multicentre study including 661
patients with CR-KP infection [7], the protective role of carbapenems
was essentially conﬁrmed for strains withMIC values ≤8mg/L, which
represented around 30% of isolates in that cohort. On the other hand,
carbapenem-sparing regimens are advocated by some authors for
reducing carbapenem use in the context of infection control and
antimicrobial stewardship programmes aimed to contain the high
endemicity of CR-KP [10].
To assess the impact on 14-day mortality of a combination
therapy with or without high-dose carbapenem in a cohort of CR-
KP BSI patients with high-level carbapenem resistance, we performed
a post hoc analysis of the Italian cohort of patients with CR-KP in-
fection, selecting thosewith BSI who received a combination therapy.
A propensity score for receiving a carbapenem-containing combi-
nation was used to adjust the survival analysis.
2. Material and methods
2.1. Study design, setting and population
We performed a post hoc analysis of a multicentre, observa-
tional cohort study of all adult (≥18 years) patients with CR-KP
infection, hospitalised in six large tertiary-care teaching hospitals
in Italy, from 01 January 2010 to 31 December 2015. Thus, with
respect to the prior report [7], the current cohort includes pa-
tients hospitalised during a longer period (6 instead of 4 years) and
in a larger number of centres (6 instead of 5 hospitals). Patients with
monomicrobial CR-KP BSI who were treated with a combination
regimenwere selected for this study. Each patient was included only
once at the time of the ﬁrst positive blood cultures (BCs, index
culture), even if more than one CR-KP BSI was reported.
2.2. Deﬁnitions
CR-KP BSI was deﬁned as isolation of a CR-KP strain in the BCs
obtained from a patient with clinical symptoms and/or signs of the
systemic inﬂammatory response syndrome [4]. BSI onset was con-
sidered as the date of the index BCs collection (the ﬁrst BCs yielding
the study isolate). BSIs were classiﬁed as low-risk or high-risk de-
pending on the source of the bacteraemia (urinary tract vs. all other
identiﬁed and unidentiﬁed sources, respectively) [11]. BSIs were
further considered as hospital-acquired, healthcare-associated or
community-acquired, according to Friedman’s criteria [12].
Septic shock was deﬁned as sepsis associated with organ dys-
function and persistent hypotension despite volume replacement
[13].
Combination therapy was deﬁned as a regimen including two
or more antibiotics, with at least one agent showing in vitro activ-
ity against the CR-KP isolate from BCs. Appropriate empirical
antibiotic therapy was deﬁned as treatment with at least one drug
that had in vitro activity against the infecting organism, initiated
within 48 h of the index BCs, and given in adequate dosage [14].
2.3. Data
Data were collected in a standardised case report form. Under-
lying diseases were recorded according to the Charlson comorbidity
index. Invasive abdominal procedures included open abdominal
surgery, endoscopic abdominal surgery and percutaneous drain-
age. Corticosteroid therapy was deﬁned by 16 mg prednisone-
equivalent/day for >15 days; neutropenia was deﬁned as <500
neutrophil cells/μL of blood for ≥7 days. Clinical severity at BSI onset
was assessed according to APACHE III score and septic shock cri-
teria [13]. Therapeutic variables included: administered antibiotics
with their dosage, schedule, and duration. All cause 14-day mor-
tality was collected for outcome. Patients were followed until hospital
discharge or in-hospital mortality.
2.4. Microbiological study
Isolates were identiﬁed with the Vitek 2 system (bioMérieux,
Marcy l’Etoile, France) and/or by matrix-assisted laser desorption
ionization-time-of-ﬂight (MALDI-TOF) mass spectrometry (MALDI
Biotyper, Bruker Daltonics GmbH, Leipzig, Germany, or Vitek-MS,
bioMérieux). The in vitro susceptibility of the isolates was as-
sessed with the Vitek 2 system (bioMérieux) or the Sensititre broth
microdilution method (Trek Diagnostic Systems, Cleveland, OH).
Results were interpreted in accordance with the European Com-
mittee on Antimicrobial Susceptibility Testing (EUCAST) clinical
breakpoints.
2.5. Statistical analysis
Categorical variables were expressed as absolute numbers and
their relative frequencies. Continuous variables were expressed as
mean ± standard deviation (SD) if normally distributed, or as median
and interquartile range (IQR) if not normally distributed.
To analyse risk factors for 14-day mortality, non-survivors and
survivors were compared. All the variables with a P-value ≤ 0.1 at
the univariate analysis were entered into a multivariate Cox back-
ward regression model after assuming for proportional hazards.
Patients were considered from the date of index BCs to death or until
14 days. Combination therapy with or without a carbapenem was
introduced as the explanatory variable of interest. A propensity score
for receiving carbapenem combination therapy was further added
to the model.
The propensity score—the probability of receiving a carbapenem
combination therapy—was calculated using a non-parsimoniousmul-
tivariate logistic regression model in which the outcome variable
was the use of carbapenem. The following variables were intro-
duced into the model: age, sex, chronic renal failure, chronic liver
failure, chemotherapy, corticosteroid treatment, abdominal inva-
sive procedure, Charlson comorbidity index, healthcare-associated
BSI, colistin-resistant strain, septic shock at BSI onset, carbapenem
MIC, combination therapy containing gentamicin, and combina-
tion therapy containing tigecycline. The validity of the model was
assessed by estimating goodness-of-ﬁt to the data with the Hosmer-
Lemeshow test (69%) and the ROC curve analysis with an area-
under-the-curve of 0.75 (95%CI 0.71–0.79).
Statistical signiﬁcancewas considered for P values <0.05. The soft-
ware used for the analysis was SPSS (SPSS; version 21.0).
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3. Results
A total of 595 patients were analysed according to the study cri-
teria. All strains were K. pneumoniae carbapenemase (KPC) producers,
mostly KPC-3; 77% of them showed a carbapenem MIC ≥16 mg/L.
Overall, 428 (71.9%) patients received combination therapy con-
taining a carbapenem. This consisted of meropenem administered
at high doses (6 g/day) and by extended infusion (each infusion lasted
3 h) in all the cases. The remaining 167 (29.1%) patients received a
combination therapy without a carbapenem. Comparison of the two
groups is shown in Table 1.
A total of 127 (21.3%) patients died within 14 days after BSI onset.
Comparison of non-surviving and surviving patients showed sig-
niﬁcant differences for the Charlson comorbidity index (median 4
vs. 2, P < 0.001), APACHE III score at BSI onset (median 27 vs. 19,
P < 0.001), underlying chronic renal failure (26% vs. 15.4%, P = 0.002),
admission to a surgical ward (10.2% vs. 22.4%, P = 0.002), septic shock
at BSI onset (40.9% vs. 12.8%, P < 0.001), and colistin resistance (27.6%
vs 20.5%, P = 0.09) (see Table 2).
Themultivariate Cox regression analysis showed that the Charlson
comorbidity index (HR 1.31, 95%CI 1.20–1.43, P < 0.001), septic shock
at BSI onset (HR 3.14, 95%CI 2.19–4.50, P < 0.001), and isolation of
a colistin-resistant strain (HR 1.52, 95%CI 1.02–2.24, P < 0.001) were
independently associated with 14-day mortality, whereas admis-
sion to a surgical ward (HR 0.44, 95%CI 0.25–-0.78, P = 0.005) was
a protective factor. The carbapenem-containing combination (HR
0.69, 95%0.47–1.00, P = 0.05) also remained in the ﬁnal model as a
protective factor, but with borderline signiﬁcance (see appendix
Table S1). When adjusted for the propensity score, the variables that
remained in the model were the Charlson comorbidity index (HR
1.65, 95%CI 1.10–2.46, P < 0.001), corticosteroid therapy (HR 1.93,
95%CI 1.22–3.04, P = 0.005), admission to a surgical ward (HR 0.44,
95%CI 0.24–0.78, P = 0.005), septic shock at BSI onset (HR 4.70, 95%CI
3.03–7.27, P < 0.001), colistin-resistant strain (HR 1.65, 95%CI 1.10–
2.46, P = 0.005), and carbapenem-containing combination (HR 0.64,
95%CI 0.43–0.95, P = 0.03) (appendix Table S1). Stratifying the model
for the carbapenem MIC, the beneﬁt of combination therapy with
an HD carbapenemwas also observed for strains with a carbapenem
MIC ≥16 mg/L (see Fig. 1).
4. Discussion
This is the ﬁrst study that analyses the outcome of patients with
CR-KP BSI treated with combination therapy, with or without a high-
dose meropenem, using the propensity score for accounting of
population imbalances. Our results conﬁrm previous data about the
beneﬁt of using a high-dose carbapenem as backbone in the com-
bination regimens for CR-KP BSI.
The deﬁnition of combination therapy for carbapenem-resistant
infection is a matter of debate [15]. Some experts deﬁne combina-
tion therapy as any regimen includingmore than one antibiotic with
Table 1
Comparison of patients with carbapenem-resistant Klebsiella pneumoniae blood-
stream infection who received combination therapy with and without high-dose
carbapenem.
Combination
with
carbapenem
N = 428 (%)
Combination
without
carbapenem
N = 167 (%)
P
Demographic variables
Male sex 269 (62.9) 97 (58.1) 0.30
Age (years) (median, IQR) 66, 54–76 65, 54–76 0.67
Underlying conditions
Charlson score (median, IQR) 3, 2–6 3, 1–4 0.007
APACHE III score (median, IQR) 21, 13–36 19.5, 15–38.5 0.64
Chronic renal failure 83 (19.4) 22 (13.2) 0.09
Haemodialysis 59 (13.8) 14 (8.4) 0.09
Chronic liver disease 46 (10.7) 8 (4.8) 0.02
Neutropenia 55 (12.9) 26 (15.6) 0.42
Corticosteroid therapy 79 (18.5) 42 (25.1) 0.07
Chemotherapy 59 (13.8) 35 (21) 0.03
Abdominal invasive procedures 193 (45.1) 88 (52.7) 0.10
Transferred from an LTCF 20 (4.7) 14 (8.4) 0.11
Admission ward at BSI onset
Medical ward 176 (41.1) 70 (41.9) 0.93
Surgical ward 78 (18.2) 40 (24) 0.13
Intensive care unit 169 (39.5) 56 (33.5) 0.19
Days of hospital stay before
BSI (median, IQR)
50, 29–77 42, 27.2–76.5 0.19
Characteristics of BSI
Low-risk source 87 (20.3) 38 (22.8) 0.57
High-risk source 341 (79.7) 129 (77.2) 0.57
Septic shock 71 (16.6) 41 (24.6) 0.02
Healthcare-associated 28 (6.5) 20 (12) 0.03
Hospital-acquired 385 (90) 146 (87.4) 0.37
Characteristics of the strain
MeropenemMIC ≤ 8 mg/L 103 (24.1) 64 (38.3) 0.001
MeropenemMIC ≥ 16 mg/L 325 (75.9) 103 (61.7)
Colistin-resistant 97 (22.7) 34 (20.4) 0.58
Therapeutic management
Colistin-containing regimen 286 (66.8) 122 (73.1) 0.17
Tigecycline-containing regimen 320 (74.8) 143 (85.7) 0.004
Gentamicin-containing regimen 170 (39.7) 113 (67.7) <0.001
Outcome
14-day mortality 85 (19.9) 42 (25.1) 0.18
In-hospital mortality 122 (28.5) 54 (32.3) 0.36
Abbreviations: BSI bloodstream infection; IQR interquartile range; LTCF long-term
care facility.
Table 2
Comparison of patients with CR-KP BSI who died within 14 days after infection onset
(date of positive index blood cultures) and survivors.
Non-survivors
N = 127 (%)
Survivors
N = 468 (%)
P
Demographic variables
Male sex 77 (60.6) 289 (61.8) 0.84
Age (years) (median, IQR) 66, 57–77 66, 53–76 0.18
Underlying conditions
Charlson score (median, IQR) 4, 3–6 2, 2–4 <0.001
APACHE III score (median, IQR) 27, 17–41 19, 13–35 <0.001
Chronic renal failure 33 (26) 72 (15.4) 0.002
Haemodialysis 20 (15.7) 53 (11.3) 0.22
Chronic liver disease 16 (12.6) 38 (8.1) 0.16
Neutropenia 17 (13.4) 64 (13.7) 1
Corticosteroid therapy 34 (26.8) 87 (18.6) 0.05
Chemotherapy 18 (14.2) 76 (16.2) 0.58
Abdominal invasive procedures 60 (47.2) 221 (47.2) 1
Transferred from an LTCF 10 (7.9) 24 (5.1) 0.27
Admission ward at BSI onset
Medical ward 59 (46.5) 187 (40) 0.22
Surgical ward 13 (10.2) 105 (22.4) 0.002
Intensive care unit 55 (43.2) 170 (36.3) 0.18
Characteristics of BSI
Low-risk source 25 (19.7) 100 (21.4) 0.71
High-risk source 102 (80.3) 368 (78.6)
Septic shock 52 (40.9) 60 (12.8) <0.001
Characteristics of the strain
MeropenemMIC ≤ 8 mg/L 32 (25.2) 135 (28.8) 0.44
MeropenemMIC ≥ 16 mg/L 95 (74.8) 333 (71.2)
Colistin-resistant 35 (27.6) 96 (20.5) 0.09
Antibiotic management
Inadequate empirical treatment 76 (59.8) 291 (62.2) 0.68
Carbapenem-containing
combination
85 (66.9) 343 (73.3) 0.18
MeropenemMIC ≤ 8 mg/L 15/85 (17.6) 88/343 (25.7) 0.15
MeropenemMIC ≥ 16 mg/L 70/85 (82.4) 255/343 (74.3) 0.15
Combination without
carbapenem
42 (33.1) 125 (26.7) 0.18
1 active drug 28/42 (66.7) 90/125 (72) 0.56
> 1 active drug 14/42 (33.3) 35/127 (28) 0.56
Abbreviations: BSI bloodstream infection; IQR interquartile range; LTCF long-term
care facility.
246 M. Giannella et al. / International Journal of Antimicrobial Agents 51 (2018) 244–248
activity against Gram-negative bacteria (regardless of their in vitro
activity against the infecting organism) [16], and others consider
combination therapy as regimens including two or more in vitro
active drugs [6]. As our objective was to assess the impact on
outcome of meropenem use in carbapenem-resistant infections, we
chose combinations with at least one in vitro active drug, because
clinicians usually choose the meropenem companion based on in
vitro susceptibility tests.
In a retrospective study of 141 CR-KP BSIs collected at two New
York City hospitals from 2006–2013, the aim of the authors was to
assess patient outcome according to the number of in vitro active
drugs used, and whether an extended-spectrum β-lactam
(meropenem or extended-spectrum cephalosporin) was adminis-
tered [15]. Of the 111 isolates for which meropenem MICs were
available, 90% had a meropenem MIC ≥16 mg/L. A lower propor-
tion of patients treated with meropenem died (24% vs. 37%), but
the difference was not statistically signiﬁcant, including after ad-
justing for meropenem MIC (≤8 mg/L or ≥16 mg/L) or meropenem
dosing category (conventional, or high-dose administered by ex-
tended infusion). There was also no difference between single and
multiple in vitro active drug used [15].
We reached different results by analysing a larger number of pa-
tients, investigating only the role of high-dose meropenem
administered by extended infusion among patients treated with a
combination regimen, and using the propensity score for account-
ing of possible imbalances. Indeed, in our univariate analysis, the
14-day mortality rate was not statistically signiﬁcantly different
between patients treated with and without HD meropenem (19.9%
vs. 25.1%, P = 0.18). However, the use of meropenem remained a pro-
tective factor in the multivariate model, and the level of signiﬁcance
increased after adjusting the analysis for the propensity score. Fur-
thermore, we stratiﬁed our multivariate model for the meropenem
MIC and observed a beneﬁt of HD meropenem combination for
strains with meropenem MIC ≥16 mg/L, which represented 77% of
overall strains. This could be explained by recent observation that
high-dose/prolonged-infusion regimens of meropenem can reach
the pharmacokinetic/pharmacodynamic target in patients with BSI
caused by CR-KP with meropenemMICs up to 32–64 mg/L, but not
for higher values [17,18]. Unfortunately, the lack of a punctual
meropenemMIC in our strains with meropenemMIC ≥16mg/L pre-
vented us from establishing for which level of carbapenem resistance
the use of carbapenems is still useful. Thus, the impact of
carbapenemMIC on outcome in patients treated with carbapenems
for CR-KP BSI should be further investigated.
Our study has some limitations. The study was not originally
designed to analyse the impact of treatment on outcome, but to
create an observational registry of severe infections with CR-KP.
The adjustment of multivariate analysis for the most important
confounding factors and for the propensity score should minimise
this limitation. However, we acknowledge that the inclusion of pro-
pensity score still leads to residual confounding. Nevertheless,
although there are some methodological drawbacks (retrospec-
tive observational study, lack of punctual meropenem MIC), the
study has some important strengths: i) it is focused only on pa-
tients receiving carbapenem vs. non-carbapenem combination
treatments; ii) it comprises a large number of patients with true
CR-KP infection, as we selected only those with BSI; iii) the
meropenem administration schedule was homogeneous (use of high
doses by extended infusion); and iv) being an observational study,
it reﬂects what happens in real life.
To conclude, in a population of patients receiving combination
therapy for CR-KP BSI, with 77% of isolates showing a carbapenem
MIC ≥16 mg/L, the use of carbapenem seems to be associated with
better outcome. Further studies, particularly clinical trials, should
be performed to assess the level of carbapenem resistance for which
the carbapenems are still useful.
Funding: No funding.
Competing interests: None.
Fig. 1. Cox regression analysis of survival stratiﬁed for carbapenem MIC. CMT: combination with meropenem treatment: 0 no, 1 yes. Panel A and Panel B show cumulative
survival at 14 days from CR-KP BSI onset for patients who did or did not receive carbapenem combination therapy, it was adjusted for all the covariates included in the Cox
regression model and the propensity score. The model was further stratiﬁed according to the meropenem MIC ≤8 mg/L (Panel A), MIC ≥16 mg/L (Panel B), the overall aHR
for the variable carbapenem combination therapy (CMT) was: 0.63, 95%CI 0.41–0.96, P = 0.03.
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